A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Published on Mar 1, 2018
· DOI :10.1093/JCAG/GWY009.147
Jean-Frederic Colombel164
Estimated H-index: 164
(Mount Sinai Hospital),
Sheldon Sloan15
Estimated H-index: 15
(Janssen Pharmaceutica)
+ 4 AuthorsS. R. Targan16
Estimated H-index: 16
(Cedars-Sinai Medical Center)
Source
Abstract
References0
Newest
Cited By1
Newest
#1Heather Catt (RMIT: RMIT University)H-Index: 1
#2Keith Bodger (University of Liverpool)H-Index: 26
Last. Dyfrig A. Hughes (Bangor University)H-Index: 50
view all 4 authors...
Background and Objective Regulatory approval of biosimilars often depends on extrapolating evidence from one clinical indication to all of those of the originator biologic. We aimed to develop a quantitative benefit-risk analysis to assess whether the resulting increase in the uncertainty in the clinical performance of biosimilars (i.e. risk) may be countered by their lower pricing (benefit).
1 CitationsSource